

The bHLH/PAS transcription factor singleminded 2s promotes mammary gland lactogenic differentiation

Elizabeth Wellberg, Richard P. Metz, Caitlin Parker and Weston W. Porter*

SUMMARY

We have previously demonstrated that the bHLH/PAS transcription factor, singleminded 2s (*Sim2s*), is required for proper mammary ductal morphogenesis and luminal epithelial differentiation. Furthermore, loss of *Sim2s* in breast cancer cells resulted in downregulation of epithelial markers and acquisition of a basal-like phenotype. The objective of this study was to further define the role of *Sim2s* in mammary differentiation. We found that *Sim2s* is developmentally regulated throughout mammary gland development with highest expression during lactation. Mammary glands from nulliparous mice expressing *Sim2s* driven by the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter were morphologically indistinguishable from wild-type mice but displayed hallmarks of precocious lactogenic differentiation. These included elevated expression of the milk protein genes *Wap* and *Csn2*, and apical localization of the lactation marker Npt2b. Consistent with the in vivo results, *Sim2s* enhanced prolactin-mediated *Csn2* expression in HC11 and CIT3 mouse mammary epithelial cells, and downregulation of *Sim2s* by shRNA in HC11 cells inhibited *Csn2* expression. Chromatin immunoprecipitation (ChIP) analyses of the *Csn2* gene found that *Sim2s* associates with the *Csn2* promoter and re-ChIP experiments showed that *Sim2s* interacted with the RNA II polymerase (RNAPII) complex. Together, these data demonstrate, for the first time, that *Sim2s* is required for establishing and maintaining mammary gland differentiation.

KEY WORDS: singleminded 2s, Mammary, Lactation, Beta-casein, Mouse

INTRODUCTION

Defining mechanisms that contribute to establishing and maintaining cellular differentiation is crucial for advancing our understanding of cellular development and a novel approach for targeting cancer therapies. A key feature of differentiation involves activation of transcription networks controlling global gene expression to ensure cell commitment to a specific phenotype. In the mammary gland, differentiation of the mammary epithelium takes place throughout the reproductive lifetime of the female. During puberty, terminal end bud (TEB) structures form and are responsible for ductal elongation. As the ducts mature, the cells differentiate into luminal or myoepithelial cells. During pregnancy, alveolar structures form and the luminal epithelium begins to acquire the ability to produce milk. When the offspring are weaned, the majority of alveolar epithelial cells die and the gland regresses, but it maintains the ability to expand in response to subsequent pregnancies. The mammary alveolar epithelial cells respond to the hormone prolactin by initiating a cascade of events leading to activation and nuclear translocation of Stat5a, which binds to regulatory elements of milk protein genes, increasing their expression (Happ and Groner, 1993; Li and Rosen, 1995). Although prolactin-mediated Stat5a activation is central to alveolar epithelial cell function, it is not the only pathway responsible for initiating mammary gland specification towards terminal differentiation. Other transcription factors, including glucocorticoid receptor (GR; Nr3c1 – Mouse Genome Informatics), CCAAT-enhancer binding protein-beta (Cebpb), Elf5 and Gata3 have also been shown to play a role in lactogenic differentiation (Kabotyanski et al., 2006; Kourou-Mehr et al., 2006; Oakes et al., 2008; Seagroves et al., 2000). Thus, commitment to

cellular differentiation in the mammary gland appears to require activation and coordination of multiple signaling pathways to insure specific mammary lineage commitment is achieved.

Singleminded 2s (*Sim2s*) is a member of the bHLH/PAS family of transcription factors and one of two orthologs of *Drosophila sim*. In fruit flies, *sim* is considered a ‘master regulator’ of differentiation that is both necessary and sufficient for proper midline cell differentiation during central nervous system development (Chang et al., 2001; Menne et al., 1997; Nambu et al., 1990). In mice, loss of both *Sim2s* alleles leads to severe developmental abnormalities in the diaphragm, ribs, cartilage and palate, suggesting that *Sim2s* plays a role in the differentiation of many tissue types (Goshu et al., 2002; Shamblo et al., 2002). We have recently shown that *Sim2s* is expressed in human breast epithelial cells and is downregulated in primary human breast cancer samples (Kwak et al., 2007). Furthermore, reestablishment of *Sim2s* in highly invasive cancer cells significantly inhibits growth and motility, suggesting that *Sim2s* is a breast tumor suppressor (Kwak et al., 2007). In addition, we found that *SIM2s* expression is suppressed by NOTCH and CEBP β and that loss of *SIM2s* in normal human breast and mouse mammary epithelium induces an invasive basal/stem cell-like phenotype (Gustafson et al., 2009; Laffin et al., 2008). *Sim2s*-null mouse mammary glands do not undergo proper ductal elongation or luminal differentiation (Laffin et al., 2008). These data suggest that *Sim2s* is required for establishing and/or maintaining differentiation during normal mammary development. As loss of *Sim2s* results in lethality shortly after birth, transplant studies were used to evaluate the requirement of *Sim2s* for nulliparous mammary development. This technique did not allow us to evaluate the role of *Sim2s* in lactogenic differentiation; therefore, the objective of this study was to further define the function of *Sim2s* in the developing mammary epithelium using alternative models.

Mammary ductal epithelial cells are the primary targets of breast cancer, and much effort has gone into determining the mechanisms governing their development and function. Although it is evident

Department of Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843-4458, USA.

*Author for correspondence (wporter@cvm.tamu.edu)

that *Sim2s* is required for mammary ductal development, and that loss of *Sim2s* promotes the acquisition of a basal phenotype, it remains unclear what role *Sim2s* plays in promoting mammary epithelial cell differentiation. Consistent with a role for *Sim2s* in mammary epithelial differentiation, we report here that *Sim2s* is developmentally regulated, showing maximal expression during mid-lactation when the mammary gland undergoes terminal differentiation. To further address the role of *Sim2s* in mammary development, we have generated a transgenic mouse expressing hemagglutinin (HA)-tagged *Sim2s* targeted to mammary epithelium by the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter. Analysis of MMTV-*Sim2s* transgenic females revealed precocious lactogenic differentiation, and overexpression of *Sim2s* in HC11 and CIT3 mouse mammary epithelial cells markedly increased *Csn2* expression following exposure to lactogenic hormones. These studies describe, for the first time, a role for *Sim2s* in regulating mammary differentiation in vitro and in vivo, and might shed light on the nature of the relationship between *Sim2s* and breast cancer progression.

MATERIALS AND METHODS

Chemicals

Ovine prolactin (Prl) was obtained from the National Hormone and Peptide Program (NHPP), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and Dr Albert F. Parlow (Harbor-UCLA Medical Center).

Animals

Nulliparous females were harvested during estrus as determined by vaginal smears and, unless otherwise indicated, all females were primiparous. All animals were housed three per cage under a standard 12-hour photoperiod. The animals were provided with access to food and water ad libitum. All procedures were approved by the University Laboratory Animal Care Committee at Texas A&M University.

Cell culture

HC11 cells were grown in RPMI 1640 media (Gibco) supplemented with 10% calf serum (Atlanta Biologicals), 50 µg/ml gentamycin (Gibco), 5 µg/ml insulin (Sigma) and 10 ng/ml epidermal growth factor (EGF; Sigma). To induce differentiation in HC11 cells, confluent plates were given fresh media for 3 days followed by 24 hours of priming in RPMI 1640 media supplemented with 10% charcoal-stripped horse serum, 50 µg/ml gentamycin, 5 µg/ml insulin and 1 µg/ml hydrocortisone (Sigma). After priming, fresh priming medium containing 1 µg/ml ovine Prl was added with fresh media every 24 hours. CIT3 cells were grown in DMEM/F12 supplemented with 2% calf serum, 1% Pen-Strep (Gibco), 5 µg/ml insulin and 5 ng/ml EGF. Confluent cells were treated with growth media lacking EGF and containing 3 µg/ml hydrocortisone and 3 µg/ml ovine Prl.

RNA isolation and reverse transcription

RNA isolation and reverse transcription (RT) reactions were performed on cultured cells as previously described (Metz et al., 2006). RNA was isolated from tissue using Trizol reagent (Invitrogen), followed by purification using a Qiagen RNeasy Mini Kit as described (Kwak et al., 2007).

In situ hybridization

In situ hybridization was performed as previously described (Wilkens, 1993). Briefly, ³⁵S-uridine triphosphate (Amersham Pharmacia Biotech, Piscataway, NJ, USA)-labeled antisense and sense probes of mouse *Sim2s* cDNA were made using the Riboprobe In Vitro Transcription Systems Kit (Promega). The TOPO TA Cloning Kit (Invitrogen) was used to subclone a 437 bp RT-PCR product that was used generate sense and antisense probes using the primers 5'-AAATCAGCTAAACCCAAAAACACAAA-3' and 5'-AGCATTCACAGGAGAAGGCTCAGAA-3'. Mammary glands from day 7 lactating mice were fixed in 4% paraformaldehyde, embedded in paraffin and cut into 5 µm sections. After deparaffinization and rehydration, sections were pretreated with 20 µg/ml proteinase K and 0.1 mM

triethanolamine/acetic anhydride before being coated with labeled probe and incubated overnight at 55°C. Slides were washed with increasing stringency using 5× SSC, followed by 50% formamide/2× SSC/100 mM β-mercaptoethanol for 30 minutes each at 65°C. Slides were then treated with 20 µg/ml ribonuclease A for 30 minutes at 37°C, followed by final washes of 2× SSC and 0.1× SSC for 15 minutes at 65°C, and dehydrated. To visualize the ³⁵S-uridine triphosphate label, slides were dipped in photographic NTB-2 emulsion (Kodak, Rochester, NY, USA) and exposed for 3 days. D-19 developer and fixer (Kodak) were used to develop the slides, followed by hematoxylin counterstain.

PCR

RT-PCR and qRT-PCR were performed as described previously (Kwak et al., 2007). Primers used for qRT-PCR reactions include: *Sim2s*, sense 5'-AACCAGTCCCGTGGTTGAC-3' and antisense 5'-ACTCTGAGG-AACGGCGAAAA-3'; *Wap*, sense 5'-TCAGTCCATGTTCCAAAAAGC-3' and antisense 5'-CTCGTTGGTTTGGCAGATGA-3'; *Csn2*, sense 5'-TGTGCTCCAGGCTAAAGTTCAC-3' and antisense 5'-GGTTGAGC-CTGAGCATATGG-3'; *Lalba*, sense 5'-GAATGGGCTGTGTTTT-ATTCA-3' and antisense 5'-TGTGCTGCCGTTGTCTGTT-3'; *Wdnl1*, sense 5'-CGCCCCACGCAGTT-3' and antisense 5'-GCCAGAG-CACGATGGATCTG-3'; and *Cldn7*, sense 5'-TCCCTGGTGTG-TGGCTTCT-3' and antisense 5'-ACAGCGTGTGCACTTCATG-3'. Primers used for RT-PCR reactions include: *Sim2s* transgene, sense 5'-AAGAACCAACCCATATCCCC-3' and antisense 5'-GGCATAATGCG-GCACATCATAAGG-3'; *Gapdh*, sense 5'-CTAACATCAAATGGGGT-GAGG-3' and antisense 5'-TCATACTGGCAGGTTTCTCC-3'; and actin exon, sense 5'-TACAGCTTACCACCACAGC-3' and antisense 5'-AAGGAAGGCTGGAAAAAGAGC-3'. The *Csn2* promoter primer sequence has been described elsewhere (Kabotyanski et al., 2006).

Generation of MMTV-*Sim2s*-HA mice

To generate transgenic mice, the *Sim2s* coding sequence containing a hemagglutinin (HA) tag on the 3' end was cloned into the MMTV-KCR transgene cassette, *pMKBP* (kindly provided by Dr Jeff Rosen, Baylor College of Medicine, Houston, TX, USA). Mice (FVB background) were generated in the Department of Molecular and Cellular Biology Transgenic Mouse Core, Baylor College of Medicine, under the supervision of Dr Francisco DeMayo. Two MMTV-*Sim2s* lines (3841 and 3829) were generated that transmitted the transgene through the germline as detected by PCR genotyping and immunohistochemistry for the HA epitope tag. However, one line (3829) was found to also have *Sim2s* expression in tissues outside of the mammary gland, including the hypothalamus and lung, and therefore was not used for these studies. All procedures were approved and followed the guidelines set forth by the Texas A&M Animal Use and Care Committee.

Immunostaining

Immunohistochemical analyses were carried out as previously described (Kwak et al., 2007). Following incubation in blocking solution, primary antibodies were added overnight. Antibodies used included HA (Sigma), *Sim2s* (Millipore), Npt2b (Alpha Diagnostics), β-casein (Santa Cruz), aquaporin 5 (Alpha Diagnostics), P-Tyr Stat5a/b (Advantex Bioreagents) and normal IgG (Upstate). Tissue processing and Hematoxylin and Eosin (H&E) staining were performed by the Histology Core Facility in the Texas A&M University College of Veterinary Medicine & Biomedical Sciences.

Wholemout analysis

Wholemout analysis was performed as previously described (Laffin et al., 2008). To determine gross ductal branching, wholemount mammary glands were imaged using a stereo microscope equipped with a digital camera and analyzed using NIH Image software. Ductal penetration was defined as the mean average of the length from the point of implantation to the ends of the three longest ducts in each mammary gland. These three ducts were used to calculate the number of branch points, or lateral ducts, per millimeter by averaging the number of unbranched and ramified ducts. The number of branch points directly contacting a vertical reference line, drawn through the center of each mammary gland, were counted directly from pictures of whole mounts.

Western blot

Cells were washed in 10 ml PBS, collected in 2 ml PBS containing complete protease inhibitor (CPI; Roche), pelleted and resuspended in lysis buffer (20 mM Tris-Cl pH 8.0, 137 mM NaCl, 10% glycerol, 1% NP-40 and 2 mM EDTA) containing CPI and phosphatase inhibitors (sodium orthovanadate, sodium fluoride and sodium molybdate). Cell lysates were incubated with rocking at 4°C for 30 minutes, centrifuged at 16,000 *g* for 10 minutes and the supernatant was saved for western blot analysis. Protein concentration was estimated using the RCDC Assay (BioRad). Samples were diluted in water and 6× loading buffer, boiled for 5 minutes and subjected to SDS PAGE. Proteins were transferred to PVDF membranes and blocked for 1 hour to overnight in PBS or TBS containing 0.5% Tween-20 and 5% non-fat milk. Following incubation with primary and secondary antibodies, membranes were developed using the Amersham ECL Plus Kit (Amersham Pharmacia Biotech).

Retroviral transduction

Lentiviral transduction of HC11 and CIT3 cells was performed as previously described (Kwak et al., 2007).

Chromatin immunoprecipitation assays

Crosslinking was achieved by the addition of 1% formaldehyde directly to culture media for 10 minutes at room temperature with gentle agitation, followed by the addition of glycine at 1.25 mM. Monolayers were washed twice with ice-cold PBS and collected in 2 ml PBS plus CPI. Cell pellets were resuspended in SDS lysis buffer containing CPI and incubated for 10 minutes on ice. Lysates were sonicated 10×10 seconds, which resulted in fragments of 200-1200 kb. Chromatin was diluted 5-fold in chromatin immunoprecipitation (ChIP) dilution buffer containing CPI and pre-cleared with 80 μl salmon sperm DNA/protein A/G agarose beads (Upstate) 2×30 minutes at 4°C with rocking. Antibodies were added overnight followed by the addition of 60 μl beads for one hour. Beads were washed for 10 minutes at 4°C with each of the following solutions: low salt buffer, high salt buffer, LiCl buffer and twice in TE buffer (Tris, EDTA) at room temperature. Complexes were eluted at room temperature in 10% SDS and 0.1 M sodium bicarbonate. Crosslinks were reversed by addition of 0.3 M NaCl and 1 μl 10 mg/ml RNase A and incubated at 65°C for 5 hours. Two and a half volumes of 100% EtOH were added and samples were placed at -20°C overnight. Following centrifugation for 10 minutes at 16,000 *g*, pellets were resuspended in 100 μl water containing Tris-HCl pH 6.5, EDTA and 1 μl 20 mg/ml proteinase K. Samples were incubated at 45°C for 1.5 hours and DNA was purified using Qiagen PCR Purification Kit (Qiagen). Two microliters were used for subsequent PCR analysis. For re-ChIP experiments, chromatin was incubated with antibody overnight at 4°C after pre-clearing. Eighty microliters of protein A or protein G agarose beads were added for 1 hour at 4°C and were washed according to standard ChIP protocol. Following TE washes, beads were incubated with 1 volume of 20 mM dithiothreitol (DTT) for 30 minutes at 37°C with agitation. Supernatants were collected and diluted to 1000 μl with re-ChIP Dilution Buffer (Upstate). Ten percent of the eluate was reserved for input and the remaining eluate was divided in half for no antibody control and immunoprecipitation with a secondary antibody, respectively. After overnight incubation with the antibody, immune complexes were precipitated with agarose beads and washed/eluted according to standard ChIP protocol. Antibodies used in ChIP analyses include Ach3 (Upstate), Sim2s (Millipore), RNAPII (Abcam), Stat5 (Millipore) and normal IgG (Upstate).

RESULTS

Sim2s is differentially expressed during mammary gland development

Based on our previous studies, we hypothesized that *Sim2s* plays a role in establishing and/or maintaining mammary epithelial cell phenotypes. Initially, we investigated *Sim2s* expression during mouse mammary gland development by qRT-PCR. Total RNA isolated from mouse mammary tissues at various developmental time points was analyzed for the expression of the *Sim2s* isoform as we have previously shown that mouse mammary epithelial cells do




Fig. 1. *Sim2s* expression is developmentally regulated in mouse mammary tissues. (A) Total RNA isolated from C57 mouse mammary glands ($n=3$ animals per group) at weeks 4 and 10 of virgin development (V4 and V10), days 6 and 16 of pregnancy (P6 and P16), days 1 and 7 of lactation (L1 and L7) and day 3 of involution (I3) was used for qRT-PCR analysis of *Sim2s* expression. (B) In situ hybridization analysis of *Sim2s* mRNA from 5-week-old virgin (top) and L7 (middle) mouse mammary glands. The sense control is shown in the bottom panel. Left images are Hematoxylin and Eosin (H&E)-stained adjacent sections. (C) Immunohistochemical (ICH) staining of L7 FVB mouse mammary glands for *Sim2s* (left panel) showing nuclear localization in the mammary epithelium. Normal rabbit IgG (right panel) was used as a negative control.

not express full-length *Sim2s* (Laffin et al., 2008). *Sim2s* expression is developmentally regulated. It is first detected in the mammary glands of four-week-old pre-pubertal mice and then decreases in mature virgin and early pregnant glands, which is consistent with *Sim2s* playing a role in the differentiation of the luminal epithelial cells as the TEBs progress through the gland (Laffin et al., 2008). *Sim2s* expression increases during late pregnancy and throughout lactation, peaking on day seven (L7) when the gland is fully differentiated (Fig. 1A). In situ hybridization confirmed that *Sim2s* mRNA increases during lactation in the luminal alveolar mammary epithelial cells (Fig. 1B). Further, immunohistochemical analysis revealed that the *Sim2s* protein is present in the nuclei of alveolar epithelial cells in L7 mammary glands (Fig. 1C). To better define the role of *Sim2s* during this process, additional samples obtained from lactation days one and four were analyzed by qRT-PCR for *Sim2s* and several milk protein markers of mammary differentiation. These data show that *Sim2s* expression progressively increases during the first week of lactation (Fig. 2A), coordinate with the milk protein genes encoding whey acidic protein (*Wap*, Fig. 2B) and β -casein (*Csn2*, Fig. 2C). Interestingly, two additional mammary differentiation markers, α -lactalbumin (*Lalba*) and *Wdm1* (encoded by *Expi*), were expressed at high levels on lactation day 1 and remained relatively unchanged over the course of lactation (Fig. 2D,E).

The observation that *Sim2s* expression coincides with mammary lactogenic differentiation led us to ask if *Sim2s* was sufficient to regulate this process. As a first step, we generated transgenic mice expressing an HA-tagged full-length *Sim2s* under control of the MMTV LTR promoter (Fig. 3A). Two separate lines of MMTV-*Sim2s*-HA mice were generated; however, PCR analyses revealed that one of the lines displayed inappropriate transgene expression with low mammary *Sim2s*-HA mRNA and high levels of transgene message in the hypothalamus, spleen and lung (see Fig. S1 in the supplementary material). In the second line, transgene expression




Fig. 2. *Sim2s* expression patterns correlate with a subset of milk protein genes during lactation. (A–E) Total RNA isolated from V8, L1, L4 and L7 FVB mammary glands ($n=5$ animals per group) was used for qRT-PCR analysis of (A) *Sim2s*, (B) *Wap*, (C) *Csn2*, (D) *Lalba* and (E) *Expi* expression. *Cldn7* was used to normalize all mammary qRT-PCR data.

was detectable exclusively in mammary tissues (Fig. 3B); therefore, further analyses were carried out using this line. Immunohistochemical analysis of wild-type (WT) and MMTV-*Sim2s*-HA mouse mammary sections using an HA antibody demonstrated that the *Sim2s* transgene was specifically found in the nucleus of mammary ductal epithelial cells (Fig. 3C; see also Fig. S1 in the supplementary material). Morphologically, MMTV-*Sim2s*-HA mammary glands were indistinguishable from WT glands throughout development. During early virgin development, TEB structures formed appropriately (Fig. 4A) and mature epithelial ducts were seen throughout the mammary fat pad by 8 weeks of age in transgenic females (Fig. 4B). During pregnancy, alveolar structures expanded and the ability of alveolar epithelial cells to undergo secretory differentiation was not impaired in glands from MMTV-*Sim2s*-HA females (Fig. 4C,D). Mammary glands of transgenic females were indistinguishable from WT glands during lactation (Fig. 4E), and MMTV-*Sim2s*-HA females were able to nurse large litters to weaning age. Following pup removal, the mammary epithelium from MMTV-*Sim2s*-HA females fully involuted and did not differ from that of WT females (Fig. 4E).

Transgenic MMTV-*Sim2s* nulliparous mice display hallmarks of precocious lactogenic differentiation

The observation that *Sim2s* levels increase during lactation, following the same pattern as a subset of milk proteins, led us to hypothesize that *Sim2s* plays a role in gene regulation during alveolar epithelial cell differentiation. Using qRT-PCR, we analyzed mature virgin WT and MMTV-*Sim2s*-HA mouse mammary tissues for *Csn2*, *Wap*, *Lalba* and *Expi* expression. Interestingly, both *Csn2* and *Wap* mRNA levels were significantly higher in eight-week-old virgin transgenic mouse mammary tissues in comparison with WT glands (Fig. 5A,B). However, expression of both *Lalba* (Fig. 5C) and *Expi* (Fig. 5D) did not change as a result of *Sim2s* expression. Although it has been reported that *Csn2* expression changes during the estrus cycle (Robinson et al., 1995), mice used in these studies cycled normally (data not shown) and all of the nulliparous females were sacrificed at estrus. Together, these data imply that *Sim2s* enhances alveolar differentiation at the molecular level and might play a role in regulating the expression of a subset of milk protein genes. To further characterize the effects of *Sim2s* on mammary cell differentiation, we analyzed sections of WT and MMTV-*Sim2s*-HA mouse mammary glands for specific epithelial cell type cell markers. aquaporin 5 (Aqp5) is an epithelial cell marker expressed on the luminal surface of ductal mammary epithelial cells in non-pregnant females (Shillingford et al., 2003). As mammary ductal epithelium differentiates into alveolar cells, Aqp5 is lost and various luminal surface solute transporters, such as Slc12a2 (Nkcc1) and Slc34a2




Fig. 3. Generation of MMTV-*Sim2s*-HA transgenic mice.

(A) Schematic diagram of the MMTV-*Sim2s*-HA targeting construct. The MMTV-LTR construct was provided by Dr Jeffrey Rosen at Baylor College of Medicine. Exons 2 and 3 (E2, E3) and Intron 2 (I2) are derived from the rabbit β -globin gene (R β G). The poly-A signal is derived from the bovine growth hormone gene (*bGHpA*). (B) RT-PCR analysis of pooled samples from three transgenic females showing expression of the *Sim2s*-HA transgene exclusively in the mammary gland. Hrt, heart; Hyp, hypothalamus; Kid, kidney; Lng, lung; Lvr, liver; Neg, negative control (water); MG, mammary gland; Pit, pituitary; Ovr, ovary; SG, salivary gland; Spl, spleen; Utr, uterus; WAT, white adipose tissue. *Gapdh* was used as a loading control. (C) IHC analysis of HA localization in mammary glands from wild-type (WT) and transgenic (*Sim2s*-HA) V8 females.

(Npt2b), are upregulated (Shillingford et al., 2003). Analysis of eight-week-old virgin WT and transgenic females revealed no differences in levels or localization of Aqp5 owing to *Sim2s* expression (Fig. 5E, top). However, apical localization of Npt2b was detected in approximately 70% of MMTV-*Sim2s*-HA glands (Fig. 5E, middle), suggesting that *Sim2s* expression is inducing a partial alveolar phenotype in these cells. In support of this, and in confirmation of the effects of *Sim2s* on *Csn2* mRNA expression, immunohistochemical analysis of WT and MMTV-*Sim2s*-HA mammary sections revealed an increase in β -casein-positive epithelial cells in virgin glands (Fig. 5E, bottom). Furthermore, we found no differences in staining for phospho-Stat5a in WT and *Sim2s* transgenics compared with glands from L7 mice (data not shown), suggesting that this phenotype is not mediated by activation of Stat5a. Together, these data indicate that *Sim2s* expression in ductal epithelium induces a gene expression profile characteristic of alveolar epithelial cells.

Sim2s is upregulated in prolactin-treated HC11 and CIT3 mouse mammary epithelial cells and is required for *Csn2* (β -casein) gene expression

To further analyze the molecular effects of *Sim2s* on mammary epithelial cell differentiation, we moved to an in vitro model system. The mouse mammary epithelial cell line HC11, derived from the COMMA-D cell line that was isolated from a mid-pregnant Balb/c mouse, has been widely used to study gene expression during lactogenic differentiation in a relatively homogeneous environment (Ball et al., 1988). Following confluent growth arrest, HC11 cells can be treated with hydrocortisone and prolactin (HC + PRL) to induce *Csn2* expression. *Sim2s* expression was analyzed in undifferentiated HC11 cells (UN) and in cells treated with HC + PRL for one or four days (Fig. 6A). We found that *Sim2s* mRNA levels began to increase within 24 hours after hormone stimulation and were elevated further by day four, which is consistent with our in vivo




Fig. 4. Assessment of mammary morphology in *Sim2s*-HA transgenic and non-transgenic female mice. (A-F) Mammary glands were isolated from (A) V5, (B) V8, (C) P6, (D) P16, (E) L2 and (F) I14 FVB females, fixed in paraformaldehyde, sectioned and stained with H&E. Scale bars: 100 μ m.

observations. Western blot analyses confirmed that both *Sim2s* and β -casein levels increased in HC11 cells after four days of hormone treatment (Fig. 6B). CIT3 cells, another COMMA-D-derived line, were also found to upregulate *Sim2s* following treatment with HC + PRL (Fig. 6C). These results indicate that these cells represent an appropriate model to study *Sim2s* regulation of mammary differentiation, and adequately recapitulate the effect on *Sim2s* seen during lactogenic differentiation in vivo.

A lentiviral transduction system was used to overexpress *Sim2s* in both HC11 and CIT3 cells. Using qRT-PCR, we determined that *Csn2* expression in cells expressing *Sim2s*, was significantly upregulated following hormone stimulation in both HC11 and CIT3 cells (Fig. 7A,C, respectively). In HC11 cells, the increase in *Csn2* was detectable in as little as four hours after treatment with HC + PRL, and continued through 24 hours (Fig. 7A). Western blot analyses confirmed increased β -casein protein in *Sim2s*-overexpressing cells (Fig. 7B), in agreement with the in vivo data. With the observation that *Sim2s* enhances β -casein, we sought to determine whether *Sim2s* is required for *Csn2* expression in vitro. To do this, we transduced HC11 cells with an shRNA construct targeting exon 6 of the *Sim2* gene. Following selection, colonies were pooled and cells were treated for 4 days with HC + PRL and analyzed for *Csn2* expression. Our results show that *Csn2* induction was reduced by approximately 50% in HC11 cells targeted with the *Sim2s* shRNA construct (*siSim2s*) in comparison with scrambled control cells (Fig. 7D). Western blot analyses revealed that although *Sim2s* levels were not completely abrogated in *siSim2s* cells, the reduction in protein was associated with a decrease in β -Casein protein in this cell line (Fig. 7E). These data suggest that *Sim2s* expression is necessary for the robust hormone-mediated induction of *Csn2* in this culture system.

Based on the data indicating a direct relationship between *Sim2s* and *Csn2* expression, and because *Sim2s* is a transcription factor, we hypothesized that it is directly involved in regulating *Csn2* gene expression. Mechanisms governing *Csn2* transcription have been well documented, and within 1 hour of prolactin treatment, increased association of Stat5a, GR, Cebp β and RNAPII can be detected at the *Csn2* proximal promoter (Kabotyanski et al., 2006). Although this region of the *Csn2* promoter does not contain consensus *Sim2s* response elements, we monitored the occupancy

of proteins around the *Csn2* transcription start site in control and *Sim2s*-overexpressing HC11 cells (Fig. 8A, solid arrows). Undifferentiated cells (UN) or cells treated for 4, 8 or 24 hours with HC + PRL were analyzed for the presence of various transcription factors using ChIP (Fig. 8B). In control cells, increased Stat5a binding to the *Csn2* promoter was observed 4 hours after HC + PRL treatment and slowly decreased thereafter. In *Sim2s* cells, Stat5a binding to the promoter region was also apparent 4 hours after HC + PRL treatment; however, the relative level of bound Stat5a was much greater in *Sim2s* HC11 cells, peaking 8 hours after hormone treatment and remaining high even at 24 hours post-induction (Fig. 8B). *Sim2s* binding to the *Csn2* promoter was also detected within 4 hours in both control and *Sim2s* HC11 cells, the latter of which maintained *Sim2s* occupancy even at 24 hours post-treatment. These changes correlated with enhanced RNAPII association at the *Csn2* promoter, and *Sim2s* cells showed both increased RNAPII binding and duration of association in comparison with control HC11 cells (Fig. 8B). Assessment of acetylated histone 3 (AcH3) binding, indicative of active transcription, did not reveal significant differences between control and *Sim2s* cells. To further examine the association pattern of *Sim2s* and the RNAPII complex, we performed re-ChIP analyses using chromatin from HC + PRL-treated WT HC11 cells with a *Sim2s* antibody. Before crosslink reversal, this chromatin was subjected to a second ChIP using an RNAPII-specific antibody. The resulting chromatin was analyzed for *Csn2* promoter and exon 7 DNA by PCR (Fig. 8C). These results show that *Sim2s* is associated with the RNAPII complex at the promoter region of the *Csn2* gene. The absence of *Sim2s* at the *Actb* gene supports that this is gene-specific and not a general effect of *Sim2s* on transcription (Fig. 8D). These results suggest that, rather than altering the accessibility of *Csn2* promoters in the population of HC11 cells, *Sim2s* is enhancing recruitment of Stat5a and RNAPII to the *Csn2* promoter, which might result in higher levels of mRNA transcription.




Fig. 5. *Sim2s* expression results in precocious expression of a subset of milk proteins and alveolar epithelial cell surface markers. (A-D) qRT-PCR was used to evaluate gene expression in samples from nulliparous wild type (WT) and transgenic (*Sim2s*) females ($n=5$ animals per group). (A) *Csn2* expression. (B) *Wap* expression. (C) *Lalba* expression. (D) *Expi* expression. *, $P<0.05$. *Cldn7* expression was used to normalize qRT-PCR data. (E) Immunohistochemical analysis of aquaporin 5 (Aqp5, top), the sodium-inorganic phosphate co-transport protein Npt2b (middle) and β -casein (bottom) in mammary glands from V8 WT and transgenic females.




Fig. 6. *Sim2s* expression is upregulated in differentiated HC11

and CIT3 cells. (A) qRT-PCR was used to detect *Sim2s* in undifferentiated HC11 cells (UN) and cells treated with HC + Prl for 1 or 4 days (PRL1 and PRL4). (B) Western blot analysis of *Sim2s* and β -casein protein levels in undifferentiated (UN) HC11 cells and PRL4 cells. (C) Western blot analysis of *Sim2s* levels in UN CIT3 cells and PRL3 cells. β -actin was used as a loading control for western analyses.

DISCUSSION

This study demonstrates, for the first time, a role for *Sim2s* in promoting differentiation of mammary alveolar epithelial cells. We have previously shown that *SIM2s* is expressed in human breast luminal epithelial cells and loss of *SIM2s* in normal human breast cell lines and mouse mammary epithelium during virgin development induces an invasive basal/stem cell-like phenotype (Laffin et al., 2008; Gustafson et al., 2009). To further evaluate the role of *Sim2s* in mammary gland development, we provide new data demonstrating that *Sim2s* is upregulated in a stepwise manner during early lactation, similar to that of *Csn2* and *Wap*, but not *Lalba* and *Expi*. Furthermore, overexpression of *Sim2s* in the mouse mammary epithelium leads to an increase of a subset of differentiation markers. In nulliparous transgenic female mice, mRNA levels of *Csn2* and *Wap*, but not *Expi* and *Lalba*, were significantly increased, revealing slight differences in the mechanisms governing regulation of these genes. Similarly, *Sim2s* expression increased in HC11 and CIT3 mouse mammary epithelial cells with lactogenic hormone treatment, and overexpressing *Sim2s* in vitro resulted in enhanced *Csn2* expression and association of Stat5a and RNAPII with the *Csn2* promoter. These results suggest that *Sim2s* is required to establish and maintain mammary ductal epithelial character in the developing virgin gland and promote lactation-dependent gene expression.

The observation that *Sim2s* expression peaks after parturition points toward *Sim2s* playing a role in the acquisition and maintenance of alveolar differentiation. Analysis of milk protein gene expression in whole tissue lysates from mammary glands of nulliparous transgenic and WT females showed that only *Csn2* and *Wap* were significantly upregulated as a result of *Sim2s* overexpression. Taken with the data showing differential patterns of milk protein gene expression during the first week of lactation, these results suggest that distinct mechanisms govern the regulation of genes in the mammary alveolar epithelium, and that *Sim2s* might participate in regulating a subset of lactation specific genes. This is consistent with previous studies that looked at milk protein gene expression in mammary glands from nulliparous mice and during pregnancy and lactation (Robinson et al., 1995). The authors showed that, during pregnancy, *Csn2* and *Wap* were detectable at different times, but in the same cell type. The expression of *Lalba* and *Expi* were temporally regulated during pregnancy as well, but were not expressed in the same cells as *Csn2* and *Wap*. During lactation, all four milk protein genes were highly expressed, but expression levels were different between cells




Fig. 7. *Sim2s* is necessary and sufficient for robust prolactin-mediated *Csn2* expression. (A) qRT-PCR analysis of *Csn2* expression in control and *Sim2s*-overexpressing HC11 cells. Total RNA was isolated from UN cells or cells treated for 4, 8 or 24 hours with HC + Prl. *Csn2* expression in control cells is shown on a smaller scale in the inset panel. (B) Western blot analysis of β -casein production in UN and HC + Prl treated control and *Sim2s*-overexpressing HC11 cells. (C) qRT-PCR analysis of *Csn2* expression in control and *Sim2s*-overexpressing CIT3 cells. Total RNA was isolated from UN cells or PRL3 cells. (D) qRT-PCR analysis of *Csn2* expression in HC11 cells stably expressing a scrambled shRNA sequence (control) or expressing shRNA targeting *Sim2s* (*siSim2s*). (E) Western blot analysis of *Sim2s* and β -casein in control and stable *shSim2s* UN cells or PRL4 cells. *, $P < 0.05$.

contained within an alveolar structure. Recently, it was reported that *Wap* expression in vivo is regulated by the demand of the nursing offspring (Creamer et al., 2009). Using a *Wap*-luciferase reporter transgenic mouse model, the results show that females nursing litters of three pups produced less *Wap* than those nursing eight pups. The increase in *Sim2s* expression during the first week of lactation might reflect a role in modulating milk protein gene transcription in response to increasing pup demand. The ChIP data obtained from HC11 cells showing enhanced recruitment of RNAPII to the *Csn2* promoter as a result of *Sim2s* overexpression supports this theory. Based on these studies, it is probable that specific factors expressed in the mammary epithelium are responsible for the variability in milk protein gene expression and for the coordinated regulation of *Csn2* and *Wap* in the same cells.

Using HC11 and CIT3 mouse mammary epithelial cell lines, we determined that *Sim2s* expression increases after stimulation with lactogenic hormones. In HC11 cells, we observed a progressive increase in *Sim2s* expression over the course of 4 days of hormone treatment, similar to the stepwise increase seen in vivo. When *Sim2s* was overexpressed in these cell lines, *Csn2* expression was significantly higher after hormone treatment, and reduction of *Sim2s* in HC11 cells revealed a necessity of *Sim2s* expression for robust *Csn2* induction. ChIP analyses in HC11 cells demonstrated increased recruitment of RNAPII and Stat5a to the *Csn2* promoter in cells overexpressing *Sim2s*. In addition, *Sim2s* itself was detected in association with the *Csn2* promoter. Significantly, the changes in RNAPII and Stat5a levels were seen without an increase in ACh3 protein in association with the same region. Re-ChIP analysis of both *Sim2s* and RNAPII showed that both proteins associated with one another in a complex at the




Fig. 8. *Sim2s* alters the binding of regulatory factors to the *Csn2* promoter region. (A) Schematic diagram of the *Csn2* gene. White boxes represent non-coding exons and black boxes represent coding exons (II-VIII). Arrows indicate the location of proximal promoter primers. (B) ChIP analyses of the proximal promoter were performed on chromatin isolated from UN HC11 cells or cells treated for 4, 8 or 24 hours with HC + Prl using the antibodies indicated to the left. (C) Re-ChIP analysis of *Sim2s* and RNAPII at the proximal promoter of *Csn2* in control cells at PRL4. Following an initial pull down with *Sim2s* antibody, chromatin was re-immunoprecipitated with RNAPII antibody and the *Csn2* promoter sequence was amplified using PCR. (D) ChIP analysis of *Sim2s* and *AcH3* occupancy of *Actnb* coding region in control and *Sim2s*-overexpressing HC11 cells is included as a control.

Csn2 promoter. These data indicate that overexpression of *Sim2s* is not simply facilitating the recruitment of transcription factors to more *Csn2* promoters in the population of cells, but rather enhancing the association of these proteins with a particular promoter. However, the mechanism by which *Sim2s* accomplishes this is unclear, although it might participate in recruiting transcriptional activators, facilitating promoter escape and/or elongation of RNAPII or acting as a transcriptional co-activator through an undefined mechanism.

Although the RNAPII complex is large, and made up of many subunits, it is possible that *Sim2s* associates with the holoenzyme to target the complex to a particular class of genes during differentiation. The conformation and subunit composition of the general transcription factors can vary depending on the tissue, the cell type within a tissue or the developmental stage of the tissue. In *Drosophila* spermatocyte development, it has been proposed that transcriptional complexes can vary in the composition of TBP-associated factors (TAFs) that, together with TBP, form TF_{II}D to regulate the expression of testis-specific genes (Hiller et al., 2004). TF_{II}D associates with promoters of genes to recruit RNAPII and promote transcription initiation. In mice, it has been shown that the cellular localization of a TAF is another level of transcriptional regulation during differentiation (Pointud et al., 2003). TAF7L was identified as a germ cell-specific paralog of TAF7. In spermatogonia, TAF7L is localized to the cytoplasm but becomes nuclear and replaces TAF7 in the TF_{II}D complex during spermatogenesis. A study performed in mouse ovaries determined that loss of TAF105 affected expression of a subset of genes associated with follicle development (Freiman et al., 2001). The authors proposed that cell type-specific subunits of TF_{II}D in mammalian cells lead to specific regulation of gene expression programs during differentiation. Cell type-specific replacements for TBP have been identified in spermatocytes and developing

myotubules as well (Deato and Tjian, 2007; Zhang et al., 2001). The participation of *Sim2s* in recruiting RNAPII to specific gene promoters could explain its association with the *Csn2* regulatory region in the absence of consensus *Sim2s* response elements.

In addition to changes in gene expression, mammary epithelial cells from MMTV-*Sim2s*-HA mice also showed apical localization of Npt2b. The sodium-inorganic phosphate transport protein is normally detected during late pregnancy and lactation and is localized to the luminal surface of alveolar epithelial cells, suggesting that *Sim2s* promotes a change in cell fate. These results are similar to the transcription factors, Elf5 and Gata3, which have also been shown to play a role in mammary lactogenic differentiation (Choi et al., 2009; Kouros-Mehr et al., 2006; Oakes et al., 2008). Loss of Elf5 in the mammary epithelium led to impaired alveolar formation and Stat5a activation (Choi et al., 2009). In addition, the authors showed that Elf5 was associated with the *Csn2* promoter. Our data indicate that *Sim2s* associates with the *Csn2* promoter in vitro and contributes to enhanced transcription of the *Csn2* gene. In cultured epithelial cells, Elf5 reduction resulted in a decrease in Stat5a, phosphorylated Stat5a and subsequently, β -casein (Choi et al., 2009). Similarly, shRNA-mediated reduction of *Sim2s* levels in HC11 cells attenuated *Csn2* mRNA and protein levels. Our studies did not investigate the requirement of *Sim2s* for alveolar expansion during pregnancy; however, overexpression of *Sim2s* in nulliparous females did not result in precocious morphological changes seen prior to lactation. Gata3 has been demonstrated to play a role in the maintenance of luminal cell fate in vivo (Kouros-Mehr et al., 2006). Loss of Gata3 impaired ductal outgrowth, alveolar formation and milk protein production. Our previous studies with *Sim2s*-null transplanted mammary epithelium suggest that *Sim2s* is also required for proper ductal outgrowth and luminal epithelial differentiation during early virgin development, which is taking place while the TEBs progress through the fat pad (Laffin et al., 2008). In the studies herein, we have demonstrated a requirement of *Sim2s* for robust prolactin-mediated *Csn2* expression. Thus, it is possible that *Sim2s* activation lies either downstream of Gata3 and Elf5 or plays a role in a parallel pathway by not only maintaining ductal epithelial cell character, but also by promoting alveolar differentiation.

A better understanding of how *Sim2s* governs mammary gland development and the consequences of this regulation might contribute significantly to cancer therapies aimed at inducing tumor cell differentiation. With increasing evidence that breast cancer progression correlates with decreased differentiation and induction of an invasive basal/stem cell-like phenotype (Contesso et al., 1987; Kouros-Mehr et al., 2008; Liu et al., 2007), deciphering signals controlling normal mammary gland development and differentiation will provide much needed insight into treating this disease. As we have shown that loss of *Sim2s* leads to a basal/stem cell-like phenotype and overexpression promotes differentiation (Laffin et al., 2008; Gustafson et al., 2009), we hypothesize that re-establishing *SIM2s* expression in highly aggressive human breast cancers will promote tumor cell differentiation and block breast cancer progression and metastasis.

Acknowledgements

We acknowledge Dr Jeffery Rosen at Baylor College of Medicine for kindly providing the MMTV-KCR-bGHpA construct. These studies were supported by grants from the National Cancer Institute (NCI) R01CA111551 (W.W.P.) and National Institutes of Environmental Health Sciences (NIEHS) T32ES007273. Deposited in PMC for release after 12 months.

Competing interests statement

The authors declare no competing financial interests.

Supplementary material

Supplementary material for this article is available at
<http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.041657/-/DC1>

References

- Ball, R. K., Friis, R. R., Schoenenberger, C. A., Doppler, W. and Groner, B.** (1988). Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. *EMBO J.* **7**, 2089-2095.
- Chang, J., Kim, I. O., Ahn, J. S. and Kim, S. H.** (2001). The CNS midline cells control the spitz class and Egr signaling genes to establish the proper cell fate of the Drosophila ventral neuroectoderm. *Int. J. Dev. Biol.* **45**, 715-724.
- Choi, Y. S., Chakrabarti, R., Escamilla-Hernandez, R. and Sinha, S.** (2009). Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. *Dev. Biol.* **2**, 227-241.
- Contesso, G., Mouriesse, H., Friedman, S., Genin, J., Sarrazin, D. and Rouesse, J.** (1987). The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. *J. Clin. Oncol.* **5**, 1378-1386.
- Creamer, B. A., Triplett, A. A. and Wagner, K. U.** (2009). Longitudinal analysis of mammogenesis using a novel tetracycline-inducible mouse model and in vivo imaging. *Genesis* **4**, 234-245.
- Deato, M. D. and Tjian, R.** (2007). Switching of the core transcription machinery during myogenesis. *Genes Dev.* **21**, 2137-2149.
- Freiman, R. N., Albright, S. R., Zheng, S., Sha, W. C., Hammer, R. E. and Tjian, R.** (2001). Requirement of tissue-selective TBP-associated factor TAFII105 in ovarian development. *Science* **293**, 2084-2087.
- Goshu, E., Jin, H., Fasnacht, R., Sepenski, M., Michaud, J. L. and Fan, C. M.** (2002). Sim2 mutants have developmental defects not overlapping with those of Sim1 mutants. *Mol. Cell. Biol.* **22**, 4147-4157.
- Gustafson, T. L., Wellberg, E., Laffin, B., Schilling, L., Metz, R. P., Zahnow, C. A. and Porter, W. W.** (2009). Ha-Ras transformation of MCF10A cells leads to repression of Single-minded-2s through NOTCH and C/EBPbeta. *Oncogene* **12**, 1561-1568.
- Happ, B. and Groner, B.** (1993). The activated mammary gland specific nuclear factor (MGF) enhances in vitro transcription of the beta-casein gene promoter. *J. Steroid Biochem. Mol. Biol.* **47**, 21-30.
- Hiller, M., Chen, X., Pringle, M. J., Suchorolski, M., Sancak, Y., Viswanathan, S., Bolival, B., Lin, T. Y., Marino, S. and Fuller, M. T.** (2004). Testis-specific TAF homologs collaborate to control a tissue-specific transcription program. *Development* **131**, 5297-5308.
- Kabotyanski, E. B., Huetter, M., Xian, W., Rijnkels, M. and Rosen, J. M.** (2006). Integration of prolactin and glucocorticoid signaling at the beta-casein promoter and enhancer by ordered recruitment of specific transcription factors and chromatin modifiers. *Mol. Endocrinol.* **20**, 2355-2368.
- Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D. and Werb, Z.** (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. *Cell* **127**, 1041-1055.
- Kouros-Mehr, H., Bechis, S. K., Slorach, E. M., Littlepage, L. E., Egeblad, M., Ewald, A. J., Pai, S. Y., Ho, I. C. and Werb, Z.** (2008). GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. *Cancer Cell* **13**, 141-152.
- Kwak, H. I., Gustafson, T., Metz, R. P., Laffin, B., Schedin, P. and Porter, W. W.** (2007). Inhibition of breast cancer growth and invasion by single-minded 2s. *Carcinogenesis* **28**, 259-266.
- Laffin, B., Wellberg, E., Kwak, H. I., Burghardt, R. C., Metz, R. P., Gustafson, T., Schedin, P. and Porter, W. W.** (2008). Loss of single-minded-2s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloproteinase 2. *Mol. Cell. Biol.* **28**, 1936-1946.
- Li, S. and Rosen, J. M.** (1995). Nuclear factor I and mammary gland factor (STAT5) play a critical role in regulating rat whey acidic protein gene expression in transgenic mice. *Mol. Cell. Biol.* **15**, 2063-2070.
- Liu, R., Wang, X., Chen, G. Y., Dalerba, P., Gurney, A., Hoey, T., Sherlock, G., Lewicki, J., Shedden, K. and Clarke, M. F.** (2007). The prognostic role of a gene signature from tumorigenic breast-cancer cells. *New Engl. J. Med.* **356**, 217-226.
- Menne, T. V., Luer, K., Technau, G. M. and Klambt, C.** (1997). CNS midline cells in Drosophila induce the differentiation of lateral neural cells. *Development* **124**, 4949-4958.
- Metz, R. P., Kwak, H. I., Gustafson, T., Laffin, B. and Porter, W. W.** (2006). Differential transcriptional regulation by mouse single-minded 2s. *J. Biol. Chem.* **281**, 10839-10848.
- Nambu, J. R., Franks, R. G., Hu, S. and Crews, S. T.** (1990). The single-minded gene of Drosophila is required for the expression of genes important for the development of CNS midline cells. *Cell* **63**, 63-75.
- Oakes, S. R., Naylor, M. J., Asselin-Labat, M. L., Blazek, K. D., Gardiner-Garden, M., Hilton, H. N., Kazlauskas, M., Pritchard, M. A., Chodosh, L. A., Pfeffer, P. L. et al.** (2008). The Ets transcription factor Elf5 specifies mammary alveolar cell fate. *Genes Dev.* **22**, 581-586.
- Pointud, J. C., Mengus, G., Brancorsini, S., Monaco, L., Parvinen, M., Sassone-Corsi, P. and Davidson, I.** (2003). The intracellular localisation of TAF7L, a paralogue of transcription factor TFIID subunit TAF7, is developmentally regulated during male germ-cell differentiation. *J. Cell Sci.* **116**, 1847-1858.
- Robinson, G. W., McKnight, R. A., Smith, G. H. and Hennighausen, L.** (1995). Mammary epithelial cells undergo secretory differentiation in cycling virgins but require pregnancy for the establishment of terminal differentiation. *Development* **121**, 2079-2090.
- Seagroves, T. N., Lydon, J. P., Hovey, R. C., Vonderhaar, B. K. and Rosen, J. M.** (2000). C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. *Mol. Endocrinol.* **14**, 359-368.
- Shamblott, M. J., Bugg, E. M., Lawler, A. M. and Gearhart, J. D.** (2002). Craniofacial abnormalities resulting from targeted disruption of the murine Sim2 gene. *Dev. Dyn.* **224**, 373-380.
- Shillingford, J. M., Miyoshi, K., Robinson, G. W., Bierie, B., Cao, Y., Karin, M. and Hennighausen, L.** (2003). Proteotyping of mammary tissue from transgenic and gene knockout mice with immunohistochemical markers: a tool to define developmental lesions. *J. Histochem. Cytochem.* **51**, 555-565.
- Wilkens, D. G.** (1993). In situ hybridization. In *Essential Developmental Biology: a Practical Approach* (ed. C. D. Stern and P. W. H. Holland), pp. 258-263. New York: Oxford University Press.
- Zhang, D., Penttila, T. L., Morris, P. L. and Roeder, R. G.** (2001). Cell- and stage-specific high-level expression of TBP-related factor 2 (TRF2) during mouse spermatogenesis. *Mech. Dev.* **106**, 203-205.